Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2011 - Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC) (on behalf of the North-Eastern German Society of Gynaecological Oncology, NOGGO)

Date

09 Sep 2017

Session

Poster display session

Presenters

Jalid Sehouli

Citation

Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372

Authors

J. Sehouli1, A. Mustea2, G. Oskay-Oezcelik3, J. Grabowski4, M. Keller5, R. Richter4, J. Harde6, S. Klawitter7, A. Wegenaer8, O. Tomé9, P. Wimberger10

Author affiliations

  • 1 Department Of Gynecology And Gynecologic Oncology, Charité Campus Virchow Klinikum, 13353 - Berlin/DE
  • 2 Gynecology, University Medicine Greifswald, Greifswald/DE
  • 3 Gynecologic Oncology, Praxisklinik Krebsheilkunde fuer Frauen, Berlin/DE
  • 4 Department Of Gynecology And Gynecologic Oncology, Charité Campus Virchow Klinikum, Berlin/DE
  • 5 C/o Charité Medical University Of Berlin, North-Eastern German Society of Gynaecological Oncology (NOGGO e.V.), Berlin/DE
  • 6 Statistics, Data Management And Medical Informatics, iOMEDICO AG, Freiburg/DE
  • 7 Biostatistics And Epidemiology, Roche Pharma AG, Grenzach-Wyhlen/DE
  • 8 Medical Affairs, Roche Pharma AG, Grenzach-Wyhlen/DE
  • 9 Department Of Gynecology, St. Vincentius-Kliniken, Karlsruhe/DE
  • 10 Gynecology And Obstetrics, Carl-Gustav-Carus University Dresden TU Dresden, Dresden/DE
More

Resources

Abstract 2011

Background

The GOG-0218 and ICON7 randomised phase III trials demonstrated the efficacy and safety of front-line BEV + CT for OC. The single-arm OTILIA study is evaluating BEV + CT in German clinical practice. In a previously reported interim analysis (ESMO & IGCS 2016), the observed safety and effectiveness were consistent with phase III results (preliminary median progression-free survival [PFS] 21.7 months). To address the lack of data on the impact of BMI on safety and clinical outcome in pts receiving CT + BEV, we performed exploratory analyses of the OTILIA dataset.

Methods

In OTILIA (NCT01697488), pts with FIGO stage IIIB–IV OC received front-line BEV + CT according to the EU label. Adverse events (CTCAE v4.0) were recorded at each cycle. Investigators assessed response per local practice. We performed post hoc exploratory subgroup analyses of the third interim dataset according to BMI and a multiple Cox regression analysis of PFS vs BMI, age, ECOG performance status, FIGO stage, residual disease and ascites as covariates.

Results

BMI was available for 785 of 808 pts. Treatment duration was similar across BMI subgroups (Table). There were no significant differences in PFS between subgroups with BMI ≤20 (hazard ratio [HR] 1.27; 95% CI 0.92–1.77) or ≥ 30 (HR 1.33; 95% CI 0.98–1.81) vs > 20–25 kg/m2 (Cox regression model) but in pts with a BMI ≤20 kg/m2, numerically more grade 3/4 and serious adverse events were observed.Table:

958P

Parameter, n (%)BMI, kg/m2
≤20 (n = 107)>20–25 (n = 329)>25–

Conclusions

In these post hoc exploratory analyses we were unable to identify any clear effect of BMI on PFS. The tolerability of BEV + systemic CT for advanced OC appeared to be influenced by BMI.

Clinical trial identification

NCT01697488

Legal entity responsible for the study

Roche Pharma AG

Funding

Roche Pharma AG

Disclosure

J. Sehouli: Membership on advisory board or board of directors: AstraZeneca, Roche, OBI Pharma, Pfizer, Clovis, NovoCure. A. Mustea: Membership on advisory board or board of directors: Roche. S. Klawitter, A. Wegenaer: Employment: Roche Pharma AG. P. Wimberger: Membership on advisory board or board of directors: Roche, Novartis, Amgen, AstraZeneca, MSD, TEVA, PharmaMar, Fresenius Biotech; Corporate-sponsored research: Roche, Novartis, Amgen, Fresenius Biotech, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.